Vaccine Scheduler

Greece: Recommended vaccinations

	General recommendation
	Recommendation for specific groups only
	Catch-up (e.g. if previous doses missed)
	Vaccination not funded by the National Health system
	Mandatory vaccination

	Birth	Months											Years
	Birth	2	3	4	5	6	11	12	15	18	19	23	2-3	4	5	6	7	9	10	11	12	13	18	19	26	50	59	60	64	65	75	≥ 76
Coronavirus disease (COVID-19)¹						COVID-19¹

tuberculosis	BCG⁷

rotavirus infection²		ROTA		ROTA		ROTA

diphtheria		D		D		D		D	D		D			D			d			d		d		d⁸
tetanus		TT		TT		TT		TT	TT		TT			TT			TT			TT		TT		TT⁸
pertussis		acP		acP		acP		acP	acp		acp			acP			acp			acp		acp		acp⁸
poliomyelitis		IPV		IPV		IPV					IPV			IPV			IPV							IPV⁸
Haemophilus influenzae type b infection		Hib		Hib		Hib		Hib	Hib		Hib					Hib								Hib
hepatitis B	HepB⁹	HepB		HepB		HepB					HepB													HepB¹⁰

pneumococcal disease³		PCV13 or PCV 15		PCV13 or PCV 15		PCV13 or PCV 15		PCV13 or PCV 15	PCV13 or PCV 15							PCV+PPSV23¹¹								PCV20						PCV20

meningococcal disease⁴		MCV4/MenB						MenC	MenC											MCV4		MCV4		MCV4/MenB

measles⁵								MEAS		MEAS			MEAS	MEAS										MEAS¹²
mumps								MUMPS		MUMPS			MUMPS	MUMPS										MUMPS¹²
rubella								RUBE		RUBE			RUBE	RUBE										RUBE¹²

varicella								VAR		VAR			VAR	VAR										VAR¹³

human papillomavirus infection																		HPV (F/M)¹⁴

influenza						IIV3																						IIV3

herpes zoster⁶																							ZOS¹⁵						ZOS¹⁶

hepatitis A													HepA				HepA							HepA¹⁷

Version:

Footnotes:

https://emvolio.gov.gr/
2 doses of RV1 (month 2 and 4) OR 3 doses of RV5 (month 2, 4 and 6)
PPSV23 recommended from 2 years of age in at-risk groups
MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB vaccine is recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
Vaccination is also recommended for infants and children up to the age of 5 years who belong to an increased risk groups and who have not been previously vaccinated
Td booster every 10 years. One of the booster dose should be with Tdacp or Tdacp-IPV
Babies born to a mother infected with hepatitis B (or with unknown status) will be offered a first vaccine dose at birth simultaneously with HB immunoglobulin. More details on follow-up schedule are available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
Three doses
PPSV is recommended in addition to PCV13 or PCV15 at least 2 months after the last dose of PCV13 in subjects > 2 years with an increased risk of disease from pneumococcal infections. A booster dose of PPSV23 is recommended 5 years after the first dose
For individuals born after 1970 (one or two doses depending on vaccination history and clinical history)
Two doses recommended to people belonging to specific occupational categories , please refer to official recommendations. Women found to be seronegative during pregnancy should be vaccinated with 2 doses in the postpartum period.
Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2023). 2 doses scheme up to 15 years with 6 months interval between doses, thereafter 3 doses. for specific at-risk groups vaccination can be extended up to 26 years.
2 doses (RZV vaccine) in immunocompromised with 2 or more episodes of herpes-zoster
ZVL for 60-75 years, RZV for immunocompromised
Two doses

More information available at:
https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/

Last update : 16 May 2023